CRKL

Overview

CRKL encodes an adaptor protein in the stress-activated MAPK cascade. In radiation-associated angiosarcoma (RT-AS), CRKL amplification is enriched compared to sporadic angiosarcoma and co-occurs with MYC amplification.

Alterations observed in the corpus

  • Amplification in 14% of RT-ANGS vs 9% of sporadic AS; part of the stress-activated MAPK cascade PMID:37350195.
  • Co-occurs with MYC amplification, FLT4, HRAS, and KMT2D alterations in breast/chest wall RT-AS PMID:37350195.
  • Involved in a singleton sense-preserving CRKL-MAPK1 fusion in prostate carcinoma (tumor P04-1084), with the ERK-2 kinase domain intact; hypothesized to constitutively activate MAPK signaling PMID:23622249

Cancer types (linked)

  • ANGS — CRKL amplification enriched in RT-AS (14%) vs sporadic AS (9%); implicated in the stress-activated MAPK cascade pathway active in RT-AS PMID:37350195.

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • CRKL is part of the stress-activated MAPK cascade pathway identified as a potential molecular target in RT-AS, alongside FLT4, HRAS, and MYC PMID:37350195.

Open questions

  • Whether targeting the CRKL-containing MAPK cascade provides therapeutic benefit in RT-AS is not established PMID:37350195.

Sources

This page was processed by entity-page-writer on 2026-04-10. - PMID:23622249

This page was processed by wiki-cli on 2026-05-09.